Cite
MLA Citation
F Pietrantonio et al.. “O-025A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients.” Annals of oncology, vol. 30, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100094624836.0x00002f